Table 1 Baseline characteristics in chronic diseases patients and the rest of the population
| Â | COPD n (%) | OA n (%) | RA n (%) | CKD n (%) | DM n (%) | The rest of the population n (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | PP | SP | PP | SP | PP | SP | PP | SP | PP | SP | PP | SP |
Statin-exposed | 617(48.4) | 292(65.9) | 696(54.8) | 175(70.9) | 181(42.1) | 60(76.9) | 442(44.3) | 386(54.8) | 4101(68.5) | 514(72.1) | 4574(57.4) | 1315(86.6) |
Age (years) (mean SD) | 68.5(8.8) | 70.2(9.0) | 68.5(8.9) | 70.8(9.6) | 63.9(11.5) | 68.1(9.9) | 66.7(14.1) | 73.6(10.5) | 60.9(11.8) | 67.3(10.5) | 64.2(11.1) | 67.1(10.9) |
Male | 297(48.1) | 169(57.9) | 295(42.5) | 95(54.6) | 46(25.4) | 29(48.3) | 248(56.4) | 239(62.2) | 2079(51.1) | 323(63.0) | 2182(47.7) | 824(62.7) |
Baseline TC (mmol/L) (mean SD) | 5.30(1.20) | 4.68(1.10) | 5.30(1.19) | 4.54(1.07) | 5.54(1.10) | 4.95(1.28) | 5.11(1.40) | 4.85(1.44) | 5.90(1.26) | 5.20(1.36) | 6.03(1.26) | 5.28(1.13) |
Simvastatin daily dose (mg) (mean SD) | 29(19) | 29(20) | 27(16) | 35(27) | 28(18) | 33(25) | 27(18) | 26(17) | 27(16) | 30(24) | 28(19) | 30(22) |
Social economic status | ||||||||||||
  1 (most deprived) | 285(46.1) | 126(43.2) | 141(20.3) | 50(28.6) | 46(25.4) | 18(30.0) | 108(25.2) | 106(28.5) | 1015(25.5) | 125(24.9) | 837(18.7) | 322(25.1) |
  2-4 | 254(42.1) | 130(45.2 | 402(58.9) | 90(52.6) | 100(56.8) | 35(58.3) | 244(56.9) | 210(56.9) | 2275(57.1) | 310(61.6) | 2681(59.8) | 760(59.1) |
  5 (most affluent) | 64(10.4) | 31(10.6) | 139(20.0) | 31(17.7) | 30(16.6) | 7(11.7) | 77(18.0) | 56(15.1) | 693(17.4) | 68(13.5) | 964(21.5) | 203(15.8) |
Concurrent use of drugs | ||||||||||||
  Analgesics | 453(73.4) | 222(76.0) | 591(84.9) | 156(89.1) | 153(84.5) | 55(91.7) | 303(68.6) | 279(72.3) | 2293(55.9) | 335(65.2) | 1897(41.5) | 666(50.7) |
  Positive inotropic drugs | 30(4.9) | 49(16.8) | 17(2.4) | 6(3.4) | 3(1.7) | 7(11.7) | 40(9.1) | 89(23.1) | 174(4.2) | 76(14.8) | 106(2.3) | 62(4.7) |
  Diuretics | 386(62.6) | 183(62.7) | 416(59.8) | 100(57.1) | 97(53.6) | 39(65.0) | 313(70.8) | 311(80.6) | 1932(47.1) | 325(63.2) | 2082(45.5) | 569(43.3) |
  Beta-adrenoceptor   blocking drugs | 97(15.7) | 78(26.7) | 290(41.7) | 94(53.7) | 57(31.5) | 41(68.3) | 204(46.2) | 208(53.9) | 1456(35.5) | 299(58.2) | 1816(39.7) | 776(59.0) |
  Hypertension and   heart failure | 373(60.5) | 213(73.0) | 431(61.9) | 124(70.9) | 82(45.3) | 48(80.0) | 303(68.6) | 272(70.5) | 2712(66.1) | 390(75.9) | 2135(46.7) | 781(59.4) |
  Nitrates & calcium-channel blockers | 393(63.7) | 235(80.5) | 415(59.6) | 130(74.3) | 99(54.7) | 51(85.0) | 301(68.1) | 302(78.2) | 1951(47.6) | 390(72.9) | 2202(48.1) | 947(72.0) |
  Anticoagulants | 43(7.0) | 49(16.8) | 56(8.1) | 13(7.4) | 13(7.2) | 13(21.7) | 64(14.5) | 104(26.9) | 237(5.8) | 103(20.0) | 227(4.9) | 97(7.4) |
  Antiplatelet drugs | 400(64.8) | 244(83.6) | 423(60.8) | 152(86.9) | 93(51.4) | 45(75.0) | 242(54.8) | 297(76.9) | 2039(49.7) | 421(81.9) | 2329(50.9) | 1107(84.2) |
  Corticosteroids | 457(74.1) | 210(71.9) | 208(29.9) | 46(26.3) | 109(60.2) | 32(53.3) | 163(36.9) | 127(32.9) | 1093(26.7) | 148(28.8) | 942(20.6) | 260(19.8) |
  NSAID drugs | 180(29.2) | 63(21.6) | 342(49.1) | 71(40.6) | 110(60.8) | 34(56.7) | 91(20.6) | 77(20.0) | 1586(38.7) | 166(32.3) | 1292(28.3) | 323(24.6) |
Co-morbidity | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
  Angina, TIA, heart failure | 56(9.1) | 142(48.6) | 34(4.9) | 17(9.7) | 6(3.3) | 9(15.0) | 33(7.5) | 140(36.3) | 169(4.1) | 109(21.2) | 187(4.1) | 508(38.6) |
  Diabetes mellitus | 111(18.0) | 33(11.3) | 131(18.8) | 14(8.0) | 36(19.9) | 11(18.3) | 67(15.2) | 60(15.5) | - | - | - | - |